Efficacy of Personalized Postoperative Epilepsy Management in Patients with Glioblastoma Utilizing IDH1 Gene Assessment
Gao-Qiang Meng,Shu Chen,Han-Bin Ye,Bao-Jun Ma,Shuo Tao,Zi Ye
DOI: https://doi.org/10.2147/ndt.s451300
IF: 2.989
2024-04-12
Neuropsychiatric Disease and Treatment
Abstract:Gao-Qiang Meng, 1, &ast Shu Chen, 2, &ast Han-Bin Ye, 1 Bao-Jun Ma, 1 Shuo Tao, 3 Zi Ye 1 1 Department of Neurosurgery, Affiliated Hospital 2 of Nantong University, Nantong First People's Hospital, Nantong, 226000, People's Republic of China; 2 Department of Endocrinology, Affiliated Hospital 2 of Nantong University, Nantong First People's Hospital, Nantong, 226000, People's Republic of China; 3 Department of Out-Patient, Affiliated Hospital 2 of Nantong University, Nantong First People's Hospital, Nantong, 226000, People's Republic of China &astThese authors contributed equally to this work Correspondence: Zi Ye, Department of Neurosurgery, Affiliated Hospital 2 of Nantong University, Nantong First People's Hospital, No. 666 of Shengli Road, Chongchuan District, Jiangsu, Nantong, 226000, People's Republic of China, Email Shuo Tao, Department of Out-patient, Affiliated Hospital 2 of Nantong University, Nantong First People's Hospital, No. 666 of Shengli Road, Chongchuan District, Jiangsu, Nantong, 226000, People's Republic of China, Tel +86 0513 81111429, Email Objective: We explored the correlation between the presence of isocitrate dehydrogenase-1 (IDH1) mutations and the incidence of postoperative epilepsy in patients with glioblastoma, as well as assessed the efficacy of preemptive administration of antiepileptic medications in mitigating the occurrence of postoperative epilepsy. Methods: Fifty-three patients who received a postoperative pathological diagnosis of glioblastoma, were enrolled in this study. Tumor specimens were subjected to IDH1 gene analysis. The patient cohort was stratified based on their IDH1 mutation status and the administration of prophylactic antiepileptic drugs during the postoperative phase. We subsequently conducted a comparative analysis of postoperative epileptic complications within each patient subgroup. Results: In the cohort of 53 patients under study, the occurrence of epilepsy was observed in 10 out of 21 patients carrying IDH1 mutations, while 5 out of 32 patients with wild-type IDH1 also experienced epilepsy, revealing a statistically significant difference (P 0.05). However, when performing a subgroup analysis, it was found that 3 out of 12 patients with IDH1 mutations who received prophylactic antiepileptic drugs experienced epilepsy, whereas 7 out of 9 patients who did not receive prophylactic antiepileptic drugs developed epilepsy, demonstrating a statistically significant difference (P 0.05). Conclusion: In individuals with IDH1 mutant glioblastoma who have undergone surgical resection, the implementation of preventive antiepileptic therapy demonstrates a potential to diminish the occurrence of postoperative epilepsy. Keywords: epilepsy, glioblastoma, isocitrate dehydrogenase-1, prophylactic antiepileptic therapy Gliomas represent a group of malignant neoplasms that originate from glial cells and constitute approximately 24% of all tumors affecting the central nervous system, with malignant variants accounting for approximately 80.9% of this category. Among gliomas, glioblastoma stands out as the most prevalent subtype, comprising 59.2% of all glioma cases. 1 The prevailing therapeutic modalities for glioblastoma predominantly encompass surgical intervention, complemented by comprehensive approaches including postoperative radiotherapy. 2 In certain cases, patients diagnosed with glioblastoma may manifest epilepsy as a concurrent manifestation during the diagnostic and therapeutic phases. Epilepsy represents a prevalent clinical manifestation of glioma, with reported incidences reaching up to 80% among individuals afflicted with this malignancy. 3–6 Attributes encompassing a high degree of malignancy, unpredictable peritumoral infiltration, unfavorable treatment outcomes, a short median survival period, and postoperative epilepsy, all contribute to a significant decline in the overall quality of life of patients. The question remains a matter of debate regarding whether patients without preoperative epileptic symptoms should receive -Abstract Truncated-
psychiatry,clinical neurology